Mylan Settlement: Shocking Gift at Taxpayer Expense

Washington, D.C. – Today, U.S. Congressman Lloyd Doggett (D-TX), senior member of the House Ways and Means Committee and chair of the Prescription Drug Task Force, issued the following statement after Trump's Department of Justice agreed to settle charges against Mylan's EpiPen rebate misclassification for $465 million. The misclassification could have cost taxpayers to overpay as much as $1.27 billion from 2006 to 2016, according to an estimate from the Department of Health and Human Services' Office of the Inspector General.

Rep. Doggett said:

"This sorry settlement amounts to a shocking $800 million gift to a leading price gouger at taxpayer expense. It insults families who have been crying out for relief from Mylan and is an affront to taxpayers. Once again, the Trump Administration adds another brick to the wall of broken promises, letting one of the companies that Trump said are ‘getting away with murder' keep so much of its ill-gotten gains. I have repeatedly asked the Department of Health and Human Services, Center for Medicaid and Medicare Services, and even the Federal Trade Commission to protect taxpayers and patients from the effects of EpiPen high prices. To be answered with this settlement is unacceptable."